Quest Diagnostics Added To Goldman Sachs Conviction Buy List

Quest Diagnostics DGX was added to the Conviction Buy list Wednesday morning at Goldman Sachs. The price target was raised from $66 to $78.

Goldman based its upgrade on better industry volumes, a renewed focus on cost cutting, expectations of margin expansion and improved capital allocation.

In pre-market trading, the stock was higher by nearly three percent at $64.80.